J. Matthew Singleton, Director at Viking Therapeutics, Inc. (VKTX), sold 10,300 shares at $69.50 ($716K) on 2024-09-20, disclosed to the SEC on 2024-09-20.
Scheduled sale ($716k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| VKTX | SELL | 2024-08-19 | $1.8M | — | Filing → |
| VKTX | SELL | 2024-08-14 | $2.4M | — | Filing → |
| VKTX | BUY | 2018-05-31 | $93K | — | Filing → |